After claiming an FDA de novo nod in August, Abbott (NYSE: ABT) said it plans to launch its Libre Duo dual-analyte sensor in the U.S. this December. The roll out of the new continuous glucose monitor, which also tracks ketone levels to safeguard against diabetic ketoacidosis, will come after its international debut set for this […]
Business/Financial News
MiniMed completes split from Medtronic
MiniMed (Nasdaq: MMED) is celebrating its first day as an independent diabetes tech company, with the full completion of its spinoff from the Medtronic mothership. This week Medtronic reported the final results of its exchange offer for MiniMed stock, where it divested all of its remaining equity stake in the company through the swapping of […]
BD’s IV catheters plant in Utah marks 70 years
BD (NYSE:BDX) is celebrating the 70th birthday of its major manufacturing facility in Utah, which the company said produces billions of molded components each year. Located in the town of Sandy just south of Salt Lake City, the site was founded in 1956 under Deseret Pharmaceuticals. BD acquired the plant in 1986, and today it’s […]
Abbott partners with Berry Street to add nutrition coaching to Lingo
Abbott (NYSE: ABT) is teaming up with Berry Street to offer dietitian support programs to Lingo users. Wearers of the over-the-counter continuous glucose monitor can now sign up for personalized nutrition coaching linked to their data trends, and schedule virtual one-on-one appointments with registered and insurance-covered dietitians. At the same time, Berry Street users will […]
Dexcom CFO to expand into COO role
Dexcom‘s (Nasdaq:DXCM) C-suite is seeing another of its members take on multiple roles. Its chief financial officer will now also serve as chief operating officer. Jereme Sylvain joined the diabetes tech company in 2018, and has been its CFO and executive VP since 2021. His new COO hat will add oversight of Dexcom’s global operations […]
Medtronic moves to divest final stake in MiniMed
Medtronic (NYSE: MDT) is entering the final stretch of its long-running plan to split from its diabetes technology business, with the launch of an exchange offer that will allow stockholders to swap their company shares for those of the independent MiniMed (Nasdaq: MMED). With its catalog of insulin pumps, continuous glucose monitors and other diabetes […]
Dexcom adds former Stryker CFO to board
CGM maker Dexcom (Nasdaq: DXCM) is adding the former CFO of orthopedic and surgical device giant Stryker to its board of directors. Glenn Boehnlein’s appointment was in effect yesterday — the day of the announcement. Boehnlein’s addition expands the size of Dexcom’s board to 13. Boehnlein retired from Stryker last year after 22 years with […]
MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance
MiniMed (Nasdaq: MMED) today reported Street-beating first-quarter revenue, upping its full-year sales guidance as it notched an early European regulatory win. The Northridge, California–based diabetes tech company, spun out of Medtronic earlier this year, announced a CE mark for its next-gen, app-controlled MiniMed Flex insulin pump — well ahead of the company’s calendar 2026 year-end target. […]
MiniMed Flex now integrated with Abbot’s Instinct sensor
MiniMed (Nasdaq: MMED) announced that the MiniMed Flex system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott. The MiniMed Flex system is MiniMed’s smallest and only app-controlled insulin pump. According to the company, Instinct is the world’s smallest sensor and offers up to 15 days of wear. Powered by SmartGuard technology, MiniMed Flex automatically adjusts insulin delivery, and the Meal Detection technology can […]
Senseonics sees activist investor take a major stake
Activist investor Sessa Capital has taken a sizeable stake in long-term, implantable CGM company Senseonics (NYSE: SENS), according to an SEC Schedule 13G filed today. The SEC filing lists Sessa directly owning 4,437,532 shares of Senseonics common stock, with warrants to buy another 8,000,000 shares of stock subject to a 9.9% blocker provision that prevents investors from […]
